What is Waypoint Bio?
Waypoint Bio is a New York-based biotechnology firm at the forefront of AI-driven drug discovery. The company specializes in developing next-generation therapeutics by utilizing a proprietary platform that combines spatial pooled screening with advanced machine learning models. Its core focus lies in the creation of in vivo CAR T assets, supported by a next-generation lentiviral vector technology. By integrating these high-tech methodologies, Waypoint Bio aims to address complex biological challenges, with a strategic focus on expanding its pipeline into biologics and diverse therapeutic areas. The company is currently preparing for clinical entry in China, projected for late 2026, positioning itself as a significant player in the global biotech ecosystem.
How much funding has Waypoint Bio raised?
Waypoint Bio has raised a total of $34.5M across 2 funding rounds:
Angel/Seed
$14.5M
Series A
$20M
Angel/Seed (2024): $14.5M with participation from Recode Health Ventures, Hummingbird Ventures, and Fifty Years Industries
Series A (2026): $20M led by Hummingbird Ventures, Lux Capital, General Catalyst, Time BioVentures, Mitsui & Co Global Investment, and Amplify Partners
Key Investors in Waypoint Bio
Hummingbird Ventures
A global investment firm that focuses on backing outlier founders at the earliest stages, providing significant support throughout the company lifecycle.
Lux Capital
A New York-based firm specializing in early-stage and growth-stage investments at the intersection of science and technology, including biotechnology and AI.
General Catalyst
A prominent venture capital firm that partners with founders to build enduring enterprises, focusing on transformational opportunities across healthcare and technology.
What's next for Waypoint Bio?
Looking ahead, the strategic deployment of this capital will be instrumental in scaling Waypoint Bio's operational capabilities and refining its therapeutic pipeline. The company is set to prioritize the clinical validation of its lead assets, ensuring that its AI-designed solutions meet the rigorous demands of modern medicine. As the firm moves toward its 2026 clinical milestones, the focus will shift toward establishing key partnerships and expanding its research footprint. With the backing of top-tier venture capital firms, Waypoint Bio is poised to navigate the complexities of the biotech sector, aiming to deliver transformative outcomes for patients while maintaining its trajectory as a leader in the intersection of technology and life sciences.
See full Waypoint Bio company page
